All News
Filter News
Found 1,198 articles
-
Pfizer, Moderna, Novavax and more are working to combine preventative shots for COVID-19, flu, RSV and other illnesses. Will convenience be enough to overcome vaccine fatigue?
-
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
10/31/2023
Novavax, Inc. (Nasdaq: NVAX) today announced the European Commission has granted approval for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.
-
Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
10/31/2023
Novavax, Inc. (Nasdaq: NVAX) today announced that the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
-
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
10/18/2023
Novavax, Inc. today announced that Singapore's Health Sciences Authority (HSA) has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom
10/18/2023
Novavax, Inc. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
-
Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
10/13/2023
Novavax, Inc. (Nasdaq: NVAX) today announced that it has finalized agreements with major pharmacy retailers and prominent Group Purchasing Organizations (GPO) in the U.S. to provide the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) to prevent COVID-19 in individuals aged 12 and older this vaccination season.
-
Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023
10/11/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023, October 11-15.
-
FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants
10/3/2023
oday, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula.
-
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
10/3/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Health Canada authorizes Pfizer-BioNTech COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant
9/28/2023
Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for individuals six months of age and older.
-
Health Canada authorizes Moderna COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant
9/12/2023
Health Canada has authorized the use of the Moderna SPIKEVAX™ COVID-19 vaccine targeting the Omicron XBB.1.5 subvariant for people six months of age and older.
-
The regulator Monday approved the companies’ supplemental Biologics License Applications for their respective mRNA shots formulated to more closely target currently circulating variants.
-
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - September 08, 2023
9/8/2023
Novavax, Inc. announced that Novavax granted non-qualified stock options and restricted stock units to Ian Watkins, Executive Vice President and Chief Human Resources Officer, as a material inducement for their entry into employment with Novavax.
-
Novavax to Participate in Upcoming September 2023 Conferences
9/8/2023
Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that it will participate in two upcoming investor conferences.
-
The vaccine was effective against previous COVID-19 variants but lacked efficacy against new ones, the company announced Thursday, leaving the booster no commercially viable options.
-
The biotech’s experimental vaccine has shown a neutralizing response to XBB sublineages of COVID-19, which currently dominate new cases in the U.S. and Europe.
-
Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6
8/22/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate studies.
-
The companies contend that their updated COVID-19 vaccines for the fall vaccination season can elicit strong immune responses against the virus’ currently dominant and emerging subvariants.
-
Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More
8/11/2023
Novo’s weight-loss drug Wegovy improves cardiovascular outcomes, Novavax posts surprise Q2 profit, while Nektar Therapeutics files lawsuit against Eli Lilly for misconduct in drug development deal. -
SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership
8/9/2023
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board of directors has decided to make an equity investment in Novavax, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, securing 6.5 million shares of common stock through a private placement.